Metabolic / GLP-1 Agonist Research Peptides Guide
Overview
This guide covers 6 research peptides in the Metabolic / GLP-1 Agonist category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.
Semaglutide — FDA Approved
Evidence: A | Status: FDA-approved (Ozempic for T2D, Wegovy for obesity)
Semaglutide is an FDA-approved GLP-1 receptor agonist (MW ~4113.6 g/mol, molecular formula C187H291N45O59) with 94% sequence homology to human GLP-1.
Use cases: Weight Management, Metabolic Health, Cardiovascular
Liraglutide — FDA Approved
Evidence: A | Status: FDA-approved (Victoza for T2D, Saxenda for obesity)
Liraglutide is an FDA-approved GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1. Developed by Novo Nordisk, it is approved as Victoza for type 2 diabetes and Saxenda for chronic weight management.
Use cases: Weight Management, Metabolic Health, Cardiovascular
Exenatide — FDA Approved
Evidence: A | Status: FDA-approved (Byetta for T2D, 2005; Bydureon for T2D, 2012)
Exenatide is a 39-amino-acid GLP-1 receptor agonist (MW ~4186.6 g/mol) originally derived from exendin-4, a peptide found in the saliva of the Gila monster (Heloderma suspectum).
Use cases: Metabolic Health, Weight Management
Dulaglutide — FDA Approved
Evidence: A | Status: FDA-approved (Trulicity for T2D, September 2014; cardiovascular risk reduction, 2020)
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes.
Use cases: Metabolic Health, Cardiovascular
Lixisenatide — FDA Approved
Evidence: A | Status: FDA-approved (Adlyxin for T2D, July 2016; Soliqua 100/33 combination, November 2016)
Lixisenatide is a once-daily GLP-1 receptor agonist (MW ~4858.5 g/mol) based on the exendin-4 scaffold, with a modified C-terminal tail containing six lysine residues.
Use cases: Metabolic Health
Albiglutide — FDA Approved
Evidence: A | Status: Previously FDA-approved (Tanzeum for T2D, April 2014). Voluntarily withdrawn from market July 2018 (commercial reasons, not safety).
Albiglutide (brand name Tanzeum in the US, Eperzan in Europe) was a once-weekly GLP-1 receptor agonist consisting of two copies of a modified GLP-1 sequence fused to human albumin (MW ~72,970 g/mol).
Use cases: Metabolic Health, Cardiovascular
Related Products
Semaglutide 10mg
10mg
Related Research News
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
Recent data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk even with significant weight loss. This semaglutide news adds a new dimension to GLP-1 research, with implications for metabolic and skeletal health.
Semaglutide News: Ozempic Linked to Fewer Bone Fractures Despite Greater Weight Loss
New data presented at the American Diabetes Association annual meeting suggests semaglutide (Ozempic, Wegovy) may reduce bone fracture risk, even with significant weight loss. The findings add a new layer to the safety profile of GLP-1 receptor agonists and have implications for peptide research.
FDA Targets Telehealth Companies Over Compounded Semaglutide Claims
The US FDA sent 25 warning letters to telehealth companies regarding misleading claims about compounded weight-loss drugs, including semaglutide. This action highlights regulatory concerns over the promotion of unapproved versions of drugs like Ozempic and Wegovy. The news carries implications for peptide researchers and the broader industry.